Cargando…

Convalescent-anti-SARS-CoV-2-plasma: Transfusion reaction during off-label therapy: case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569097/ http://dx.doi.org/10.1007/s40278-021-04962-z

Ejemplares similares

Convalescent-anti-SARS-CoV-2-plasma: Anaphylactic shock and transfusion reaction: case report
Publicado: (2020)

Convalescent-anti-SARS-CoV-2-plasma: Transfusion-related acute lung injury following off-label use: case report
Publicado: (2021)

Convalescent-anti-SARS-CoV-2-plasma: Febrile TACO reaction following off-label use: case report
Publicado: (2022)

Convalescent-anti-SARS-CoV-2-plasma: Lack of efficacy following off-label use: case report
Publicado: (2021)

Convalescent-anti-SARS-CoV-2-plasma: Lack of efficacy following off-label use: case report
Publicado: (2022)

Convalescent-anti-SARS-CoV-2-plasma: Transfusion acute circulatory overload: case report
Publicado: (2021)

Convalescent anti SARS-CoV-2 plasma/norepinephrine/tocilizumab: Lack of efficacy and off-label use: case report
Publicado: (2021)

Antibacterials/convalescent-anti-SARS-CoV-2-plasma/remdesivir: Treatment failure and off-label use: case report
Publicado: (2021)

Blinatumomab/convalescent-anti-SARS-CoV-2-plasma: B-cell depletion and off label use: case report
Publicado: (2021)

Convalescent-anti-SARS-CoV-2-plasma/dexamethasone/remdesivir: Off-label use and lack of efficacy: case report
Publicado: (2021)

Antibacterials/convalescent-anti-SARS-CoV-2-plasma/hydroxychloroquine: Off-label use and lack of efficacy: case report
Publicado: (2022)

Antivirals/convalescent-anti-SARS-CoV-2-plasma/imatinib: Haematological disorder and off label use: case report
Publicado: (2021)

Convalescent-anti-SARS-CoV-2-plasma/heparin: Lack of efficacy following an off-label treatment: case report
Publicado: (2022)

Convalescent-anti-SARS-CoV-2-plasma/immunosuppressants: SARS-CoV-2 infection, its re-infection and off label use: case report
Publicado: (2021)

Anakinra/convalescent-anti-SARS-CoV-2-plasma/prednisolone: Aggravation of SARS-CoV-2 hepatitis, SARS-CoV-2 viraemia and off-label use: case report
Publicado: (2021)

Convalescent-anti-sars-cov-2-plasma: Transfusion-related acute lung injury following off-label use: 2 case reports
Publicado: (2022)

Anakinra\Convalescent-anti-SARS-CoV-2-plasma\dexamethasone: Pulmonary Aspergillosis and off label use: 6 case reports
Publicado: (2021)

Convalescent-anti-SARS-CoV-2-plasma/enoxaparin-sodium/methylprednisolone: Various toxicities and off label use: case report
Publicado: (2021)

Remdesivir/methylprednisolone/convalescent-anti-SARS-CoV-2-plasma: Elevated aminotransferase levels and off-label use: case report
Publicado: (2021)

Azithromycin/convalescent-anti-SARS-CoV-2-plasma/steroids: Necrotising pancreatitis following off label use: case report
Publicado: (2022)

Convalescent-anti-SARS-CoV-2-plasma/dexamethasone/voriconazole: Invasive pulmonary aspergillosis, off label use and lack of efficacy: case report
Publicado: (2021)

559. Outcomes of Convalescent Plasma Transfusion for SARS-CoV2 Patients in the Intensive Care Unit
por: Khalid, Rabeeya, et al.
Publicado: (2020)

Early Transfusion of Convalescent Plasma Improves the Clinical Outcome in Severe SARS-CoV2 Infection
por: Fodor, Eszter, et al.
Publicado: (2021)

Convalescent-anti-sars-cov-2-plasma/dexamethasone/remdesivir: Lack of efficacy and off label use: case report
Publicado: (2022)

Convalescent-anti-SARS-CoV-2-plasma: Ecchymosis: case report
Publicado: (2022)

Correction to: Early Transfusion of Convalescent Plasma Improves the Clinical Outcome in Severe SARS-CoV2 Infection
por: Fodor, Eszter, et al.
Publicado: (2022)

Convalescent-anti-SARS-CoV-2-plasma/remdesivir/rituximab: COVID-19 infection, and lack of efficacy following off-label use: 20 case reports
Publicado: (2022)

Antibacterials/convalescent-anti-SARS-CoV-2-plasma/immunosuppressants: Cryptococcosis, Staphylococcus aureus infection and lack of efficacy following off-label use: case report
Publicado: (2022)

Convalescent-anti-sars-cov-2-plasma: Allergic urticaria and anaphylaxis following off label use: 2 case reports
Publicado: (2021)

Convalescent-anti-sars-cov-2-plasma/remdesivir: Sinus bradycardia, elevated ALT and off-label use: case report
Publicado: (2021)

Convalescent anti-SARS-CoV-2 plasma: Organising pneumonia: case report
Publicado: (2020)

Dynamics of anti-SARS-CoV-2 antibodies in repeat convalescent plasma donors
por: Franchini, Massimo, et al.
Publicado: (2021)

Production of anti‐SARS‐CoV‐2 hyperimmune globulin from convalescent plasma
por: Vandeberg, Peter, et al.
Publicado: (2021)

Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection
por: Shoham, Shmuel, et al.
Publicado: (2021)

Convalescent-anti-sars-cov-2-plasma/dexamethasone/favipiravir: Avascular necrosis of femoral head and off-label use: case report
Publicado: (2021)

The predictors of high titer of anti-SARS-CoV-2 antibody of convalescent plasma donors
por: Wardhani, Shinta Oktya, et al.
Publicado: (2021)

Convalescent-anti-sars-cov-2-plasma/remdesivir: Lack of efficacy during treatment of COVID-19 and off label use: 2 case reports
Publicado: (2022)

The Evidence for High-Titer Convalescent Plasma in SARS-CoV-2
por: Fisher, David L., et al.
Publicado: (2021)

Convalescent plasma for SARS-CoV-2 infection: win or learn
por: Contreras-Barbeta, Enric, et al.
Publicado: (2022)

Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors
por: Steenhuis, Maurice, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2nlqj7ipaa7476ij5cej7fvvje